UAE’s Neopharma and ASKA of Japan to build drug plant in India in $53M JV

Taj mahal on a bright day in Agra, India
UAE-based drugmaker Neopharma and ASKA Pharma of Tokyo will build a $53 million pharmaceutical manufacturing facility in India. (Somchaisom/Getty Images)

United Arab Emirates-based drugmaker Neopharma and ASKA Pharmaceuticals of Tokyo entered a joint venture to build a $53 million (₹350-crore) pharmaceutical manufacturing facility to be operated by Neopharma subsidiary Omnicare Drugs India in Visakhapatnam.

The plant is expected to open by 2020 and will produce oral solid dosage forms, oral liquids and topical preparations. The capacity of the facility is projected at 3 billion tablets a year, The Hindu reported.

The joint venture aims to manufacture drugs for chronic therapies in cardiovascular diseases, the central nervous system and diabetes, along with other products from key therapeutic classes targeting Japan and the world market.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Construction is set to begin this month at a site in J.N. Pharma City. The company said it will seek cGMP accreditation from all major global health regulatory bodies.

"The partnership will enable us to transfer skills and knowledge locally," B.R. Shetty, Neopharma’s chairman, said in a statement.

Last summer, Neopharma announced it would build a $100 million plant in Abu Dhabi. That news came just weeks after the drugmaker said it would spend more than twice that for manufacturing plant and development rights to a diabetes treatment in Japan.

Suggested Articles

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.